ADVANCED SOLID TUMOR

This early-stage study tests a new drug called ONC-783 in about 20 adults with advanced solid tumors, including colorectal, ovarian, pancreatic, or breast cancer that has spread. The main goal is to find the safest dose and check for side effects. Participants must have good orga…

This early-stage study tests a new mRNA-based immunotherapy called PMC2129G12 for people with advanced solid tumors that have not responded to standard treatments. The treatment is injected directly into the tumor and is designed to help the body's immune cells attack the cancer.…

This study tests a new drug called CVL006 combined with several standard chemotherapy drugs in people with advanced solid tumors that have not responded to prior treatments. The goal is to find the safest dose and see if the combination can shrink tumors or slow their growth. Abo…

This early-phase study tests a new drug called JH021 in 60 people with advanced solid tumors that have stopped responding to standard treatments. JH021 is a bispecific antibody designed to target two cancer-related proteins (EGFR and cMET). The main goals are to check the drug's …

This study tests an experimental drug called BSI-082 in adults with advanced or spreading solid tumors that have not responded to standard treatments. In the first part, patients receive BSI-082 alone at increasing doses. In the second part, they receive BSI-082 plus another drug…

This study looks at how well a new cancer drug called envafolimab works in everyday medical practice. Envafolimab is given as a simple shot under the skin, not through an IV, making treatment faster and easier. The study will include about 120 adults with advanced solid tumors wh…

This early-stage trial tests a new drug, ISM5939, in about 159 adults with advanced or metastatic solid tumors that have not responded to standard treatments. The study has three parts: first, finding a safe dose of ISM5939 alone; second, fine-tuning the dose; and third, testing …

This early-phase study tests a new drug called MG2512 in about 116 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see how the body processes it. This is a first step to see i…

This early study tests a new treatment called CAT-101, made from a patient's own immune cells trained to attack cancer cells with specific KRAS mutations. It is given alone or with another drug (tislelizumab) to people with advanced pancreatic cancer or other solid tumors. The ma…

This study tests a new tablet, ZL-85FA, in people with advanced solid tumors such as breast, ovarian, or prostate cancer. The goal is to see if the drug is safe and can shrink tumors or stop them from growing. About 51 participants will take the tablet, and researchers will monit…

This study tests a new drug (IPG7236) combined with an immunotherapy (toripalimab) in adults with advanced solid tumors that have spread or cannot be removed. The goal is to check safety, how the body processes the drugs, and whether they shrink tumors. About 52 people will join …

This study tests two experimental drugs, TQB2930 and TQB2102, given together to people with advanced solid tumors that have a protein called HER2. The goal is to find the safest and most effective dose and see if the combination can shrink tumors. About 178 adults aged 18 to 75 w…

This is the first human study of an experimental oral drug called ACC-1898 for adults with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find a safe dose and understand how the body processes the drug. Participants will take dail…